Phase 1 Study of CS-7017

Phase 1

• Conditions: Solid Cancer not curable with, or not eligible for standard treatment(s)

• Registration Number: JPRN-jRCT2080220936
• Lead Sponsor: DAIICHISANKYO Co.,Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-12-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Histologically or cytologically diagnosed metastatic solid cancers which are not curable with, or not eligible for standard treatment(s)
-ECOG performance status: 0-1

Exclusion Criteria

-History of any of the following events within 6 months prior to start of study treatment myocardial infraction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or cerebral infraction, pulmonary embolism, deep vein thrombosis, or other clinically significant thromboembolic event, clinically significant pulmonary disease (eg severe COPD or asthma)
-Patient with a clinically active brain metastasis, or who need drugs to control adverse event like edema and pleural effusion
-Inflammatory bowel disease, or partial bowel obstruction
-Patients with any severe or uncontrolled intercurent diseases

Study & Design

• Study Type: Interventional
• Study Design: Not specified